Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: Effect of vasoactive intestinal peptide

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3261-3269

  Pérez García, Selene ^a   Juarranz, Yasmina ^a   Carrión, Mar ^a   Gutiérrez Cañas, Irene ^a   Margioris, Andrew ^b   Pablos, José L ^c   Tsatsanis, Christos ^b   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF CRETE   (Greece)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; UROCORTIN I; UROCORTIN II; UROCORTIN III; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CLINICAL ARTICLE; FIBROBLAST; HUMAN; HUMAN TISSUE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FIBROBLASTS; HUMANS; INFLAMMATION MEDIATORS; OSTEOARTHRITIS, KNEE; PHOSPHORYLATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; UROCORTINS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 80053133742     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22687     Document Type: Article

References (50)

1. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. 2003. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology 124: 961-971.
2. Abad C, Gomariz RP, Waschek JA. 2006. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: Focus on VIP and PACAP. Curr Top Med Chem 6: 151-163.
3. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P. 1998. Corticosteroid independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 275: E757-E762.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. 1988. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
5. Baigent SM. 2001. Peripheral corticotrophin-releasing hormone and urocortin in the control of the immune response. Peptides 22: 809-820.
6. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, Wilder RL. 1992. Local secretion of corticotrophin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 90: 2555-2564.
7. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, Remmers EF, Mathern P, Chrousos GP, Wilder RL. 1993. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 15: 1587-1596.
8. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL. 1997. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 82: 1279-1283.
9. Cutolo M, Straub RH, Bijlsma JWJ. 2007. Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 3: 627-634.
10. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7: 563-568.
11. Delgado M, Pozo D, Ganea D. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-290.
12. Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M, Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN. 2007. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology 148: 1524-1538.
13. Eijsbouts AM, van den Hoogen FH, Laan RF, Hermus AR, Sweep CG, van de Putte LB. 2005. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 23: 658-664.
14. Firenstein GS. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
15. Fuller-Thomson E, Stefanyk M, Brennensthul S. 2009. The robust association between childhood physical abuse and osteoarthritis in adulthood: Findings from a representative community sample. Arthritis Rheum 61: 1554-1562.
16. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. 2001. Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Des 7: 89-111.
17. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. 2006. VIP-PACAP system: New insights for multitarget therapy. Ann N Y Acad Sci 1070: 51-74.
18. Gonzalez-Rey E, Chorny A, Varela N, ÓValle F, Delgado M. 2007. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis Rheum 56: 531-543.
19. Gutiérrez-Cañas I, Juarranz Y, Santiago B, Martínez C, Gomariz RP, Pablos JL, Leceta J. 2008. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis. Brain Behav Immun 22: 312-317.
20. Herrmann M, Scholmerich J, Straub RH. 2000. Stress and rheumatic diseases. Rheum Dis Clin North Am 26: 737-763.
21. Ishizu A, Abe A, Miyatake Y, Baba T, Linuma C, Tomaru U, Yoshiki T. 2010. Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. Mod Rheumatol 20: 134-138.
22. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J. 2010. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88: 734-745.
23. Juarranz MG, Santiago B, Torroba M, Gutiérrez-Cañas I, Palao G, Galindo M, Abad C, Martínez C, Leceta J, Pablos JL, Gomariz RP. 2004. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 43: 416-422.
24. Juarranz Y, Abad C, Martínez C, Arranz A, Gutiérrez-Cañas I, Rosignoli F, Gomariz RP, Leceta J. 2005. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7: 1034-1045.
25. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. 2008. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58: 1086-1095.
26. Kageyama K, Suda T. 2009. Regulatory mechanisms underlying corticotrophin-releasing factor gene expression in the hypothalamus. Endocr J 56: 335-344.
27. Karalis KP, Kontopoulos E, Muglia LJ, Majzoub JA. 1999. Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Proc Natl Acad Sci USA 96: 7093-7097.
28. Kempuraj D, Papadopoulo NG, Lytinas M, Huang M, Kandere-Grzybpwska K, Madhappan B, Boucher W, Christodoulou S, Athanassiou A, Theoharides TC. 2004. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145: 43-48.
29. Khono M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue K, Kusaka Y, Kubo T, Elenkov IJ, Chrousos GP, Kondo M, Sano H. 2001. Urocortin expression in the synovium of patients with rheumatoid arthritis and osteoarthritis: Relation to inflammatory activity. J Clin Endocrinol 86: 4344-4352.
30. Kokkotou E, Torres D, Moss A, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C. 2006. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 177: 3355-3361.
31. Kuperman Y, Chen A. 2008. Urocortins: Emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab 19: 122-129.
32. Laburthe M, Couvineau A, Marie JC. 2002. VPAC receptors for VIP and PACAP. Receptors Channels 8: 137-153.
33. Laburthe M, Couvineau A, Tan V. 2007. Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. Peptides 28: 1631-1639.
34. Leceta J, Gomariz RP, Martínez C, Carrión C, Arranz A, Juarranz Y. 2007. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 14: 134-138.
35. Mattheos S, Christodoulou S, Kempuraj D, Kempuraj B, Karalis K, Theoharides TC. 2003. Mast cells and corticotrophin-releasing hormone (CRF) are required for experimental inflammatory arthritis. FASEB J 17: C44.
36. 2 production by corticotrophin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum 50: 1132-1145.
37. Müller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. 2007. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 9: 223.
38. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O. 2001. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotrophin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 44: 782-793.
39. Pashos KA, Kolios G, Chatzaki E. 2009. The corticotrophin-releasing factor system in inflammatory bowel disease: Prospects for new therapeutic approaches. Drug Discov Today 14: 713-719.
40. Ralph JA, Zocco D, Bresnihan B, FitzGerald O, McEvoy AN, Murphy EP. 2007. A role for type 1α corticotrophin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am J Pathol 170: 1121-1133.
41. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S. 2007. Moderate pulmonary arterial hypertension in the male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268.
42. Schmidt M, Hartung R, Capellino S, Cutolo M, Pfeifer-Leeg A, Straub RH. 2009. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in sinovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 60: 2913-2922.
43. Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, Wortsman J. 2004. Differential expression of a cutaneous corticotrophin-releasing hormone system. Endocrinology 145: 941-950.
44. Smith EM. 2008. Neuropeptides as signal molecules in common leukocytes and the hypothalamic-pituitary-adrenal axis. Brain Behav Immun 22: 3-14.
45. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A, Margioris AN. 2005. Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 579: 4259-4264.
46. Tsatsanis C, Androulidaki A, Alissafi T, Dermitzaki E, Charalampopoulos I, Roger T, Gravanis A, Margioris AN. 2006. Corticotropin releasing factor and the urocortins induce TLR4 expression in macrophages via activation of PU.1 and AP.1. J Immunol 176: 1869-1877.
47. Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN. 2007a. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 64: 1638-1655.
48. Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN. 2007b. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 210: 774-783.
49. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, Oki Y, Lino K, Sawai T. 2001. Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clin Sci 100: 577-589.
50. Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM. 2002. Corticotropin releasing hormone (CRF) antagonist attenuates adjuvant induced arthritis: Role of CRF in peripheral inflammation. J Rheumatol 29: 1252-1261.